α-methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIα in cystoprostatectomies with incidental prostate cancer

Alfredo Santinelli, Roberta Mazzucchelli, Francesca Barbisan, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli, Rodolfo Montironi

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

α-Methylacyl coenzyme A racemase (AMACR), Ki-67, and topoisomerase IIα were immunohistochemically evaluated in prostate carcinoma (PCa), high-grade prostatic intraepithelial neoplasia (HPIN), normal-looking epithelium (NEp), and atrophy in 20 cystoprostatectomy (CyP) and 20 radical prostatectomy (RP) specimens with pT2a Gleason score 6 PCa. The aim was to see whether there were differences in marker expression between CyP and RP specimens. The results showed that the proportions of AMACR-, Ki-67-, and topoisomerase IIα-positive cells in the CyP and RP specimens increased from NEp and atrophy through HPIN, away from and adjacent to PCa, to PCa. AMACR expression in PCa in CyP specimens was slightly lower than in RP specimens, but the differences were not significant; there were significant differences in Ki-67 and topoisomerase IIα indices. Our findings in marker expression in NEp, atrophy, and HPIN suggest that there are some differences in the field effects in terms of prostatic carcinogenesis between CyP and RP specimens.

Original languageEnglish (US)
Pages (from-to)657-664
Number of pages8
JournalAmerican journal of clinical pathology
Volume128
Issue number4
DOIs
StatePublished - Oct 1 2007

Keywords

  • α-methylacyl coenzyme A racemase
  • Cell proliferation
  • Cystoprostatectomy
  • High-grade prostatic intraepithelial neoplasia
  • Incidental cancer
  • Indolent cancer
  • Insignificant cancer
  • Ki-67
  • Prostate cancer
  • Significant cancer
  • Topoisomerase IIα

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'α-methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIα in cystoprostatectomies with incidental prostate cancer'. Together they form a unique fingerprint.

  • Cite this